Screening for hepatitis C in genitor-urinary medicine clinics: a cost utility analysis

K. Stein, K. Dalziel, A. Walker, L. McIntyre, B. Jenkins, A. Round, Pamela Lee Royle

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background/Aims: To estimate the cost utility (cost per QALY) of screening for hepatitis C (HCV) infection in people attending genito-urinary medicine clinics in England.

Methods: An epidemiological model of screening and diagnosis was combined with a Markov chain model of treatment with combination therapy to estimate cost utility. Parameters for the model were informed by literature review, expert opinion and a survey of current screening practice.

Results: The base case estimate was about pound85,000 per QALY. Selective screening is more cost effective. If screening is restricted to only 20% or 10% of attenders, cost utility is estimated as pound39,647 and pound34,288 per QALY. If screening is restricted only to those with a history of injecting drug use, cost utility would be pound27,138 per QALY. Estimates are particularly sensitive to acceptance rates for screening and treatment.

Conclusions: Universal screening for HCV in GUM clinics is unlikely to be cost effective. There is limited evidence to support screening of people other than those with a history of injecting drug use and even this policy should be considered with some care and in the context of further research. (C) 2003 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Original languageEnglish
Pages (from-to)814-825
Number of pages11
JournalJournal of Hepatology
Volume39
DOIs
Publication statusPublished - 2003

Keywords

  • cost utility
  • hepatitis C
  • epidemiological model
  • VIRUS-INFECTION
  • RISK-FACTORS
  • DRUG-USERS
  • SEXUAL TRANSMISSION
  • INTERFERON-ALPHA
  • SEMINAL FLUID
  • LIVER-BIOPSY
  • HCV RNA
  • SEMEN
  • RIBAVIRIN

Cite this

Stein, K., Dalziel, K., Walker, A., McIntyre, L., Jenkins, B., Round, A., & Royle, P. L. (2003). Screening for hepatitis C in genitor-urinary medicine clinics: a cost utility analysis. Journal of Hepatology, 39, 814-825. https://doi.org/10.1016/S0168-8278(03)00392-1

Screening for hepatitis C in genitor-urinary medicine clinics: a cost utility analysis. / Stein, K.; Dalziel, K.; Walker, A.; McIntyre, L.; Jenkins, B.; Round, A.; Royle, Pamela Lee.

In: Journal of Hepatology, Vol. 39, 2003, p. 814-825.

Research output: Contribution to journalArticle

Stein, K, Dalziel, K, Walker, A, McIntyre, L, Jenkins, B, Round, A & Royle, PL 2003, 'Screening for hepatitis C in genitor-urinary medicine clinics: a cost utility analysis', Journal of Hepatology, vol. 39, pp. 814-825. https://doi.org/10.1016/S0168-8278(03)00392-1
Stein, K. ; Dalziel, K. ; Walker, A. ; McIntyre, L. ; Jenkins, B. ; Round, A. ; Royle, Pamela Lee. / Screening for hepatitis C in genitor-urinary medicine clinics: a cost utility analysis. In: Journal of Hepatology. 2003 ; Vol. 39. pp. 814-825.
@article{8481cb92294b4b929f742651bc0a8dc1,
title = "Screening for hepatitis C in genitor-urinary medicine clinics: a cost utility analysis",
abstract = "Background/Aims: To estimate the cost utility (cost per QALY) of screening for hepatitis C (HCV) infection in people attending genito-urinary medicine clinics in England.Methods: An epidemiological model of screening and diagnosis was combined with a Markov chain model of treatment with combination therapy to estimate cost utility. Parameters for the model were informed by literature review, expert opinion and a survey of current screening practice.Results: The base case estimate was about pound85,000 per QALY. Selective screening is more cost effective. If screening is restricted to only 20{\%} or 10{\%} of attenders, cost utility is estimated as pound39,647 and pound34,288 per QALY. If screening is restricted only to those with a history of injecting drug use, cost utility would be pound27,138 per QALY. Estimates are particularly sensitive to acceptance rates for screening and treatment.Conclusions: Universal screening for HCV in GUM clinics is unlikely to be cost effective. There is limited evidence to support screening of people other than those with a history of injecting drug use and even this policy should be considered with some care and in the context of further research. (C) 2003 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.",
keywords = "cost utility, hepatitis C, epidemiological model, VIRUS-INFECTION, RISK-FACTORS, DRUG-USERS, SEXUAL TRANSMISSION, INTERFERON-ALPHA, SEMINAL FLUID, LIVER-BIOPSY, HCV RNA, SEMEN, RIBAVIRIN",
author = "K. Stein and K. Dalziel and A. Walker and L. McIntyre and B. Jenkins and A. Round and Royle, {Pamela Lee}",
year = "2003",
doi = "10.1016/S0168-8278(03)00392-1",
language = "English",
volume = "39",
pages = "814--825",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",

}

TY - JOUR

T1 - Screening for hepatitis C in genitor-urinary medicine clinics: a cost utility analysis

AU - Stein, K.

AU - Dalziel, K.

AU - Walker, A.

AU - McIntyre, L.

AU - Jenkins, B.

AU - Round, A.

AU - Royle, Pamela Lee

PY - 2003

Y1 - 2003

N2 - Background/Aims: To estimate the cost utility (cost per QALY) of screening for hepatitis C (HCV) infection in people attending genito-urinary medicine clinics in England.Methods: An epidemiological model of screening and diagnosis was combined with a Markov chain model of treatment with combination therapy to estimate cost utility. Parameters for the model were informed by literature review, expert opinion and a survey of current screening practice.Results: The base case estimate was about pound85,000 per QALY. Selective screening is more cost effective. If screening is restricted to only 20% or 10% of attenders, cost utility is estimated as pound39,647 and pound34,288 per QALY. If screening is restricted only to those with a history of injecting drug use, cost utility would be pound27,138 per QALY. Estimates are particularly sensitive to acceptance rates for screening and treatment.Conclusions: Universal screening for HCV in GUM clinics is unlikely to be cost effective. There is limited evidence to support screening of people other than those with a history of injecting drug use and even this policy should be considered with some care and in the context of further research. (C) 2003 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

AB - Background/Aims: To estimate the cost utility (cost per QALY) of screening for hepatitis C (HCV) infection in people attending genito-urinary medicine clinics in England.Methods: An epidemiological model of screening and diagnosis was combined with a Markov chain model of treatment with combination therapy to estimate cost utility. Parameters for the model were informed by literature review, expert opinion and a survey of current screening practice.Results: The base case estimate was about pound85,000 per QALY. Selective screening is more cost effective. If screening is restricted to only 20% or 10% of attenders, cost utility is estimated as pound39,647 and pound34,288 per QALY. If screening is restricted only to those with a history of injecting drug use, cost utility would be pound27,138 per QALY. Estimates are particularly sensitive to acceptance rates for screening and treatment.Conclusions: Universal screening for HCV in GUM clinics is unlikely to be cost effective. There is limited evidence to support screening of people other than those with a history of injecting drug use and even this policy should be considered with some care and in the context of further research. (C) 2003 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

KW - cost utility

KW - hepatitis C

KW - epidemiological model

KW - VIRUS-INFECTION

KW - RISK-FACTORS

KW - DRUG-USERS

KW - SEXUAL TRANSMISSION

KW - INTERFERON-ALPHA

KW - SEMINAL FLUID

KW - LIVER-BIOPSY

KW - HCV RNA

KW - SEMEN

KW - RIBAVIRIN

U2 - 10.1016/S0168-8278(03)00392-1

DO - 10.1016/S0168-8278(03)00392-1

M3 - Article

VL - 39

SP - 814

EP - 825

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

ER -